The Center for Drug Evaluation (CDE) has indicated that Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has had its second market filing for brolucizumab accepted for review. The filing is anticipated to be for the treatment of visual impairment resulting from macular edema associated with diabetes (DME).
Brolucizumab, recognized as a novel anti-VEGF humanized single-chain antibody fragment, is utilized for the treatment of wet age-related macular degeneration (wAMD) and DME. It was initially filed for marketing in China in August of the previous year for the use in diabetic retinopathy.
Already featured in the second batch of clinically urgently needed drugs that have been approved in overseas markets, brolucizumab was permitted for use in selected hospitals in Guangdong, as announced in February 2022. Two years later, the drug was included in the sixth batch of such drugs, specifically for the treatment of visual impairment caused by DME.- Flcube.com
